| NOVARTIS VACCINES AND DIAGNOSTICS SRL Patent applications |
| Patent application number | Title | Published |
|---|
| 20120135026 | COMBINATION NEISSERIAL COMPOSITIONS - Compositions comprising a first biological molecule from a | 05-31-2012 |
| 20120128707 | STREPTOCOCCUS PNEUMONIAE PROTEINS AND NUCLEIC ACIDS - The invention provides proteins and nucleic acid sequences from | 05-24-2012 |
| 20120093868 | HAEMOPHILUS INFLUENZAE TYPE B - Polypeptides comprising various amino acid sequences derived from | 04-19-2012 |
| 20120058146 | IMMUNOGENS FROM UROPATHOGENIC ESCHERICHIA COLI - Disclosed herein are various genes that can be included in immunogenic compositions specific for pathogenic | 03-08-2012 |
| 20120027813 | ADJUVANTED INFLUENZA VACCINES FOR PEDIATRIC USE - An influenza vaccine adjuvanted with a sub-micron oil-in-water emulsion elicits significantly higher immune responses in human pediatric populations. Compared to an existing unadjuvanted pediatric influenza vaccine, the adjuvanted vaccines provided herein can induce in children a longer persistence of high serum antibody titers and also longer seroconversion and seroprotection. The improvement in immune responses is seen for both influenza A virus and influenza B virus strains, but it is particularly marked for influenza B virus. Moreover, while the existing vaccine provides poor immunity in children after a single dose, the adjuvanted vaccine provides high seroprotection rates against the influenza A virus H3N2 subtype even after a single dose. Furthermore, the adjuvanted vaccine offers significantly better seroprotection against mismatched strains of influenza A virus. | 02-02-2012 |
| 20120020890 | STAPHYLOCOCCUS AUREUS PROTEINS AND NUCLEIC ACIDS - The invention provides proteins from | 01-26-2012 |
| 20110300171 | FACTOR H BINDING PROTEIN IMMUNOGENS - The invention relates to immunization against pathogenic bacterial strains which express or can express multiple factor H binding proteins. Certain aspects of the invention include vaccine compositions comprising at least two factor H binding proteins derived from a pathogenic bacterial strain which expresses multiple facto H binding proteins. | 12-08-2011 |
| 20110195409 | STREPTOCOCCUS PYOGENES CLASSIFICATION - The difference Lancefield T-serotypes correlate with the sequence of the pilus backbone protein (Pbp) in | 08-11-2011 |
| 20110189230 | VACCINATION WITH MULTIPLE CLADES OF H5 INFLUENZA A VIRUS - H5N1 influenza viruses isolated from animals and humans since 2003 separate into distinct clades based on hemagglutinin amino acid sequences. According to the invention, multiple clades are used in influenza immunization. Thus there is a prime-boost immunization schedule where a subject receives a priming dose of a first clade of H5 influenza A virus and a boosting dose of a second clade of H5 influenza A virus. There is also an immunogenic composition comprising hemagglutinin antigens from more than one clade of H5 influenza A virus. | 08-04-2011 |
| 20110180430 | ADJUVANTED INFLUENZA VACCINES INCLUDING CYTOKINE-INDUCING AGENTS - While oil-in-water emulsions are excellent adjuvants for influenza vaccines, their efficacy can be improved by additionally including other immunostimulating agent(s) to improve cytokine responses, such as γ-interferon response. Thus, a vaccine comprises (i) an influenza virus antigen; (ii) an oil-in-water emulsion adjuvant; and (iii) a cytokine-inducing agent. | 07-28-2011 |
| 20110166323 | CHIMERIC, HYBRID AND TANDEM POLYPEPTIDES OF MENINGOCOCCAL NMB1870 - NMB1870 is a protein in | 07-07-2011 |
| 20110104193 | COMBINATION NEISSERIAL COMPOSITIONS - Compositions comprising a first biological molecule from a | 05-05-2011 |
| 20110052620 | HYBRID POLYPEPTIDES COMPRISING GBS-80 AND SPB1 PROTEINS OF STREPTOCOCCUS - GBS antigens GBS-80 and Spb1 are expressed in a single polypeptide chain, preferably with Spb1 upstream of GBS-80. Thus the invention provides a polypeptide comprising an amino acid sequence NH | 03-03-2011 |
| 20100272755 | FERMENTATION PROCESSES FOR CULTIVATING STREPTOCOCCI AND PURIFICATION PROCESSES FOR OBTAINING CPS THEREFROM - This invention is in the field of bacterial cultures and specifically relates to the optimization of culture conditions to improve the production of bacterial capsular polysaccharides from | 10-28-2010 |
| 20100272725 | Neisserial antigens - The invention provides proteins from | 10-28-2010 |
| 20100233205 | ADJUVANTED ANTIGENIC MENINGOCOCCAL COMPOSITIONS - Compositions comprising a Neisserial antigen and a detoxified ADP-ribosylating toxin are provided. These compositions have been found useful for mucosal immunization, particularly for nasal immunization against | 09-16-2010 |
| 20100221278 | IMMUNOGENIC COMPOSITIONS FOR STREPTOCOCCUS PYOGENES - The invention includes a GAS antigen, GAS 40, which is particularly suitable for use either alone or in combinations with additional GAS antigens, such as GAS 117, GAS 130, GAS 277, GAS 236, GAS 40, GAS 389, GAS 504, GAS 509, GAS 366, GAS 159, GAS 217, GAS 309, GAS 372, GAS 039, GAS 042, GAS 058, GAS 290, GAS 511, GAS 533, GAS 527, GAS 294, GAS 253, GAS 529, GAS 045, GAS 095, GAS 193, GAS 137, GAS 084, GAS 384, GAS 202, and GAS 057. | 09-02-2010 |
| 20100158943 | ADMINISTRATION ROUTES FOR PRIMING/BOOSTING WITH INFLUENZA VACCINES - Patients receive a mucosal influenza vaccine and then receive a parenteral influenza vaccine, in that order, typically during different visits to a vaccination center. | 06-24-2010 |
| 20100041868 | Conserved neisserial antigens - To ensure maximum cross-strain recognition and reactivity, regions of proteins that are conserved between different Neisserial species, serogroups and strains can be used. The invention provides proteins which comprise stretches of amino acid sequence that are shared across the majority of | 02-18-2010 |
| 20100035285 | RAPID ELISA - A step in the enzyme-linked immunosorbent assay (ELISA) is changed from a heterogeneous phase to a homogeneous phase, to give a much shorter overall completion time. The new assay comprises the steps of (i) mixing in a homogeneous phase a sample and a first binding partner to an analyte to form a first mixing product; and (ii) exposing the first mixing product to a second binding partner to the analyte. | 02-11-2010 |
| 20090324633 | Immunogens from Uropathogenic Escherichia Coli - Disclosed herein are various genes that can be included in immunogenic compositions specific for pathogenic | 12-31-2009 |
| 20090304742 | INFLUENZA VACCINES WITH REDUCED AMOUNT OF EMULSION ADJUVANT - Influenza vaccines with oil-in-water emulsion adjuvants are known. The amount of emulsion adjuvant required for an influenza vaccine can be reduced, thereby allowing more vaccines to be made from a given amount of emulsion, and/or minimizing the amount of emulsion that has to be produced for a given number of vaccine doses. These vaccines can conveniently be made by mixing (i) an oil-in-water emulsion and (ii) an aqueous preparation of an influenza virus antigen. In one aspect, substantially equal volumes of components (i) and (ii) are used; in another aspect, an excess volume of component (ii) is used. When using substantially equal volumes, component (ii) has a hemagglutinin concentration of more than 60 μg influenza virus strain per ml. Components (i) and (ii) can be presented in kit form. | 12-10-2009 |
| 20090304739 | INFLUENZA VACCINES INCLUDING COMBINATIONS OF PARTICULATE ADJUVANTS AND IMMUNOPOTENTIATORS - Influenza vaccines containing insoluble particulate adjuvants have been found to elicit an IgG response that is primarily a TH2 response (IgG1). This response can be shifted towards a TH1 response (IgG2a) by including immunopotentiators in the compositions. Thus the invention provides an immunogenic composition comprising: (i) an influenza virus antigen; (ii) an insoluble particulate adjuvant; and (iii) a immunopotentiator. | 12-10-2009 |
| 20090298099 | Gonococcal Proteins and Nucleic Acids - The invention provides proteins from gonococcus ( | 12-03-2009 |
| 20090220547 | Reducing interference between oil-containing adjuvants and surfactant-containing antigens - Inclusion of fatty adjuvants in vaccine compositions can cause difficulties with certain antigenic components, particularly with antigens that include a surfactant component. A method for preparing an immunogenic composition comprising an antigen and a fatty adjuvant involves purification of the antigen substantially in the absence of surfactant. Where surfactants cannot be avoided, the following are combined: (i) an antigen component that includes a surfactant and (ii) a fatty adjuvant component, to give a composition in which the weight ratio of said fatty adjuvant to said surfactant is less than 1000:1. | 09-03-2009 |
| 20090220544 | ADJUVANTED VACCINES WITH NON-VIRION ANTIGENS PREPARED FROM INFLUENZA VIRUSES GROWN IN CELL CULTURE - An immunogenic composition comprising (i) a non-virion influenza virus antigen prepared from a virus grown in cell culture; and (ii) an adjuvant. Preferred adjuvants comprise oil-in-water emulsions. | 09-03-2009 |
| 20090136547 | ZWITTERIONIZATION OF CAPSULAR SACCHARIDES - Capsular saccharides are typically anionic. In the invention, however, cationic groups are introduced, such that the modified saccharide has a repeating unit which includes both cationic and anionic groups. These cationic and anionic groups can be balanced to give a zwitterionic repeating unit. These modifications can convert a saccharide that is normally a T-independent antigen into one that can activate T cells without requiring conjugation to a carrier. Typically, the invention modifies an anionic bacterial capsular saccharide antigen by converting a neutral group in the saccharide into a cationic group e.g. to change —NHAc to —NH | 05-28-2009 |
| 20090104218 | Group B Streptococcus - Polypeptides and nucleic acids from | 04-23-2009 |
| 20090047353 | CHANGING TH1/TH2 BALANCE IN SPLIT INFLUENZA VACCINES WITH ADJUVANTS - The invention seeks to avoid components in split vaccines that could cause an excessive Th2 response. Thus the invention provides an immunogenic composition comprising a split influenza virus antigen and a Th1 adjuvant, wherein the antigen is preferably prepared from a virus grown in cell culture (e.g., it is free from egg proteins). | 02-19-2009 |
| 20090047293 | Compositions Comprising Yersinia Pestis Antigens - Disclosed are several | 02-19-2009 |
| 20080312137 | Fed Batch Culture Methods for Streptococci - This invention relates to the optimization of culture conditions to improve the production of bacterial capsular polysaccharides from | 12-18-2008 |
| 20080220010 | Immunogenic Compositions for Streptococcus Agalactiae - This application relates to Group B | 09-11-2008 |
